Neil Kirby
Director/Board Member at Orphan Technologies Ltd.
Profile
Neil Kirby is currently a Director at Orphan Technologies Ltd.
Previously, he worked as the President & Chief Executive Officer at Edimer Pharmaceuticals, Inc. from 2009 to 2015.
He also held positions as a Director at Genetics Institute LLC, Head-Regulatory Affairs at Biogen MA, Inc., Program Executive at Vertex Pharmaceuticals, Inc., Senior VP-Strategic Product Development at Transkaryotic Therapies, Inc. from 2002 to 2011, and Chief Development Officer at Stromedix, Inc. Dr. Kirby earned a doctorate degree from the University of London.
Neil Kirby active positions
| Companies | Position | Start |
|---|---|---|
Orphan Technologies Ltd.
 Orphan Technologies Ltd. Pharmaceuticals: MajorHealth Technology Orphan Technologies Ltd. engages in the manufacturing of biopharmaceutical drugs. It develops novel therapies for patients suffering from rare disorder and classical homocystinuria. The company is headquartered in Rapperswil, Switzerland. | Director/Board Member | - |
Former positions of Neil Kirby
| Companies | Position | End |
|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | - |
Edimer Pharmaceuticals, Inc.
 Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Chief Executive Officer | - |
Stromedix, Inc.
 Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Stromedix, Inc. develops novel drugs to treat fibrosis and fibrotic organ failure. The company was founded by Michael Gilman in 2006 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Genetics Institute LLC
 Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Director/Board Member | - |
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | General Counsel | - |
Training of Neil Kirby
| University of London | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| Private companies | 6 |
|---|---|
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
Stromedix, Inc.
Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Stromedix, Inc. develops novel drugs to treat fibrosis and fibrotic organ failure. The company was founded by Michael Gilman in 2006 and is headquartered in Cambridge, MA. | Health Technology |
Edimer Pharmaceuticals, Inc.
Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Health Technology |
Orphan Technologies Ltd.
Orphan Technologies Ltd. Pharmaceuticals: MajorHealth Technology Orphan Technologies Ltd. engages in the manufacturing of biopharmaceutical drugs. It develops novel therapies for patients suffering from rare disorder and classical homocystinuria. The company is headquartered in Rapperswil, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Neil Kirby
